ATE323151T1 - Ex-vivo isolierte cd25+cd4+ t zellen mit immunsuppressiver aktivität und deren anwendungen - Google Patents

Ex-vivo isolierte cd25+cd4+ t zellen mit immunsuppressiver aktivität und deren anwendungen

Info

Publication number
ATE323151T1
ATE323151T1 AT02750989T AT02750989T ATE323151T1 AT E323151 T1 ATE323151 T1 AT E323151T1 AT 02750989 T AT02750989 T AT 02750989T AT 02750989 T AT02750989 T AT 02750989T AT E323151 T1 ATE323151 T1 AT E323151T1
Authority
AT
Austria
Prior art keywords
cells
applications
vivo isolated
clones
immunosupressive activity
Prior art date
Application number
AT02750989T
Other languages
English (en)
Inventor
Maria Grazia Roncarolo
Megan Levings
Original Assignee
Fond Telethon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23131593&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE323151(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fond Telethon filed Critical Fond Telethon
Application granted granted Critical
Publication of ATE323151T1 publication Critical patent/ATE323151T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02750989T 2001-05-30 2002-05-29 Ex-vivo isolierte cd25+cd4+ t zellen mit immunsuppressiver aktivität und deren anwendungen ATE323151T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29403001P 2001-05-30 2001-05-30

Publications (1)

Publication Number Publication Date
ATE323151T1 true ATE323151T1 (de) 2006-04-15

Family

ID=23131593

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02750989T ATE323151T1 (de) 2001-05-30 2002-05-29 Ex-vivo isolierte cd25+cd4+ t zellen mit immunsuppressiver aktivität und deren anwendungen

Country Status (6)

Country Link
US (2) US20040173778A1 (de)
EP (1) EP1409650B1 (de)
JP (1) JP2004527263A (de)
AT (1) ATE323151T1 (de)
DE (1) DE60210623T2 (de)
WO (1) WO2002097070A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050101012A1 (en) 2001-03-12 2005-05-12 Gerold Schuler CD4+CD25+ regulatory T cells from human blood
US8222033B2 (en) 2002-08-12 2012-07-17 Argos Therapeutics, Inc. CD4+CD25− T cells and Tr1-like regulatory T cells
GB0302167D0 (en) * 2003-01-30 2003-03-05 Leuven K U Res & Dev T cell phenotype
US7651855B2 (en) 2003-04-17 2010-01-26 The Trustees Of The University Of Pennsylvania Regulatory T cells and their use in immunotherapy and suppression of autoimmune responses
AU2004256154A1 (en) * 2003-07-11 2005-01-20 Blasticon Biotechnologische Forschung Gmbh Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical proparations
WO2005037190A2 (en) * 2003-09-03 2005-04-28 Dendritherapeutics, Inc. Multiplex vaccines
JP2007538000A (ja) * 2004-01-08 2007-12-27 リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア 制御性ｔ細胞は自己免疫を抑制する
JP5805358B2 (ja) * 2005-02-02 2015-11-04 ブルース・ミルネ・ホール 特異抗原に活性化したｃｄ４＋、ｃｄ２５＋ｔ細胞
EP1712615A1 (de) * 2005-04-15 2006-10-18 Txcell In vitro Herstellung einer Zellpopulation mittels Nährzellen
JP2008029440A (ja) * 2006-07-27 2008-02-14 Asahi Kasei Kuraray Medical Co Ltd 白血球除去治療の効果の予測方法及びキット
EP2052076A4 (de) 2006-08-02 2010-07-14 Newsouth Innovations Pty Ltd Verfahren zur identifizierung von gegen ein antigen aktivierten, cd8 exprimierenden cd4+cd25+-t-zellen
WO2008017517A1 (en) 2006-08-11 2008-02-14 Life Sciences Research Partners Vzw Immunogenic peptides and their use in immune disorders
CN101548008B (zh) 2006-10-04 2013-04-17 詹森药业有限公司 失活的人工抗原提呈细胞的制备及其在细胞疗法中的用途
WO2009101204A2 (en) 2008-02-14 2009-08-20 Life Sciences Research Partners Vzw Elimination of immune responses to viral vectors
US20120009678A1 (en) 2008-02-14 2012-01-12 Jean-Marie Saint-Remy Immunotherapy targeting intracellular pathogens
WO2009101205A2 (en) 2008-02-14 2009-08-20 Life Sciences Research Partners Vzw Immunogenic control of tumours and tumour cells
US20100291117A1 (en) 2009-05-18 2010-11-18 Tinghua Cao Method for ex-vivo expansion of regulatory t cells with enhanced suppressive function for clinical application in immune mediated diseases
US8075895B2 (en) 2009-09-22 2011-12-13 Janssen Pharmaceutica N.V. Identification of antigenic peptides from multiple myeloma cells
US10023847B2 (en) 2010-11-25 2018-07-17 Imnate Sarl Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination
GB201201511D0 (en) 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
KR101520534B1 (ko) * 2012-05-07 2015-05-21 고려대학교 산학협력단 말초혈액단핵구 유래 자연 살해세포의 유도 및 증식 방법
CN107991829A (zh) * 2012-12-20 2018-05-04 三菱电机株式会社 图像读取装置
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
US10729791B2 (en) 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
EP3352782B1 (de) 2015-09-25 2021-03-31 ImCyse SA Verbesserte verfahren und verbindungen zur beseitigung von immunreaktionen auf therapeutische mittel
WO2017182528A1 (en) 2016-04-19 2017-10-26 Imcyse Sa Novel immunogenic cd1d binding peptides
EP3551749B1 (de) 2016-12-07 2023-09-27 East Carolina University Zusammensetzungen und verfahren zur in vitro-kultivierung und/oder expansion von regulatorischen t-zellen
CN108220237B (zh) * 2017-12-20 2020-11-06 中国科学院遗传与发育生物学研究所 一种人的nk/t细胞系
CN115710576A (zh) 2018-02-01 2023-02-24 Nkmax有限公司 产生天然杀伤细胞的方法和用于治疗癌症的组合物
CA3151724A1 (en) 2019-09-26 2021-04-01 Simrit PARMAR Compositions comprising regulatory t cells and methods of making and using the same
WO2022005462A1 (en) * 2020-06-30 2022-01-06 Tr1X, Inc. Poly-donor cd4+ t cells expressing il-10 and uses thereof
WO2022204523A1 (en) 2021-03-25 2022-09-29 Cellenkos, Inc. Populations of enriched regulatory t cells and methods for producing same
JP2024512808A (ja) 2021-04-05 2024-03-19 ヤンセン バイオテツク，インコーポレーテツド Ｃａｌｒ及びｊａｋ２ｔ細胞受容体

Also Published As

Publication number Publication date
WO2002097070A1 (en) 2002-12-05
DE60210623T2 (de) 2007-02-15
US20040173778A1 (en) 2004-09-09
DE60210623D1 (de) 2006-05-24
EP1409650A1 (de) 2004-04-21
JP2004527263A (ja) 2004-09-09
EP1409650B1 (de) 2006-04-12
US20090010950A1 (en) 2009-01-08

Similar Documents

Publication Publication Date Title
DE60210623D1 (de) Ex-vivo isolierte cd25+cd4+ t zellen mit immunsuppressiver aktivität und deren anwendungen
IL273422A (en) Methods and systems for extracorporeal organ treatment
WO2003000038A3 (en) Compositions and methods for modulating plant development
DE60310576D1 (en) 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer
ATE472598T1 (de) Cd4+cd25+ regulatorische t-zellen aus menschlichem blut
SG163588A1 (en) Methods for identifying agents and conditions that modulate neurogenesis
WO2017066561A3 (en) Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
ATE305448T1 (de) Phenylalaninderivate als herbizide
SG167664A1 (en) 2,4-pyrimidinediamine compounds and their uses
BR0207775A (pt) Lipossomos anfotéricos métodos para carregamento dos mesmos com ingredientes ativos e sua utilização
EP1551953A4 (de) Modulation von stamm- und vorläuferzelldifferenzierung,versuchsmuster und entsprechende anwendungen
BRPI0513477A (pt) composições e processos de uso de proteìna 4 semelhante a angiotensina
NO20091976L (no) Nye forbindelser
WO2004015077A3 (en) Compositions and methods for neural differentiation of embryonic stem cells
EP4491635A3 (de) Anti-ccr8 antikörper
SE0302129D0 (sv) Farmaceutiska kompositioner med antibiotisk aktivitet
CA3156248A1 (en) ANTI-CD37-MAYTANSINE ANTIBODY CONJUGATES AND METHODS OF USE THEREOF
MX2007005202A (es) Polisacaridos de estreptococo modificados y usos de los mismos.
JOP20220206A1 (ar) الخلايا التائية واستخداماتها
IL187489A0 (en) Novel substrate for rpn 11 enzymatic activity
ATE404602T1 (de) Wässrige polyurethanzubereitungen
ATE363890T1 (de) Kationische polymerisate und deren verwendung in kosmetischen formulierungen
NO20064715L (no) Deteksjon, isolering og anvendelse av renalase (monoamin aksidase C)
ATE324446T1 (de) Mutante formen von etxb und ctxb und ihre verwendung als träger
MX2024003331A (es) Moleculas de union a d3 y usos de estas.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties